BioSpace News Archive

AltruBio Inc. today announced that management will participate in the following May 2024 medical conferences.

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time to report financial results for the first quarter 2024 and to highlight recent corporate progress.

Benitec Biopharma Inc. today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.

Denali Therapeutics Inc. today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial.

Corbus Pharmaceuticals Holdings, Inc. today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion as part of the BTIG Obesity Health Forum, to be held virtually on May 8, 2024.

4D Molecular Therapeutics today announced presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Seattle, Washington on May 5-9, 2024.

Prime Medicine, Inc. today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will participate in a panel discussion at the 27th Annual Milken Institute Global Conference entitled “Things That Will Blow Your Mind.”

Catalyst Pharmaceuticals, Inc. today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will participate at the upcoming BofA Securities Health Care Conference.

Akari Therapeutics, Plc and Peak Bio Inc. announced completion of a joint portfolio prioritization review pursuant to which the combined entity, following completion of the previously announced merger of Akari and Peak, will focus on Peak’s ADC platform technology and Akari’s PAS-nomacopan Geographic Atrophy program.

Creyon Bio, Inc. (“Creyon”) and Cajal Neuroscience, (“Cajal”) today announced a partnership to develop novel OBMs for neurodegenerative diseases.